Daly AK - Search Results

1

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

King BP, Khan TI, Aithal GP, Kamali F, Daly AK. King BP, et al. Among authors: daly ak. Pharmacogenetics. 2004 Dec;14(12):813-22. doi: 10.1097/00008571-200412000-00004. Pharmacogenetics. 2004. PMID: 15608560

2

CYP2C9 polymorphism and warfarin dose requirements.

Daly AK, Day CP, Aithal GP. Daly AK, et al. Br J Clin Pharmacol. 2002 Apr;53(4):408-9. doi: 10.1046/j.1365-2125.2002.01572_6.x. Br J Clin Pharmacol. 2002. PMID: 11966680 Free PMC article. No abstract available.

3

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.

Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK. Bahadur N, et al. Among authors: daly ak. Biochem Pharmacol. 2002 Dec 1;64(11):1579-89. doi: 10.1016/s0006-2952(02)01354-0. Biochem Pharmacol. 2002. PMID: 12429347

4

Pharmacogenetics of oral anticoagulants.

Daly AK, King BP. Daly AK, et al. Pharmacogenetics. 2003 May;13(5):247-52. doi: 10.1097/00008571-200305000-00002. Pharmacogenetics. 2003. PMID: 12724615 Review.

5

CYP3A5 phenotype-genotype correlations in a British population.

King BP, Leathart JB, Mutch E, Williams FM, Daly AK. King BP, et al. Among authors: daly ak. Br J Clin Pharmacol. 2003 Jun;55(6):625-9. doi: 10.1046/j.1365-2125.2003.01798.x. Br J Clin Pharmacol. 2003. PMID: 12814460 Free PMC article.

6

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK. Thervet E, et al. Among authors: daly ak. Transplantation. 2003 Oct 27;76(8):1233-5. doi: 10.1097/01.TP.0000090753.99170.89. Transplantation. 2003. PMID: 14578760

7

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Kamali F, et al. Among authors: daly ak. Clin Pharmacol Ther. 2004 Mar;75(3):204-12. doi: 10.1016/j.clpt.2003.10.001. Clin Pharmacol Ther. 2004. PMID: 15001972

8

Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.

Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG, Caldwell J, Day CP. Aithal GP, et al. Among authors: daly ak. Hepatology. 2004 May;39(5):1430-40. doi: 10.1002/hep.20205. Hepatology. 2004. PMID: 15122773

9

Genetic regulation of warfarin metabolism and response.

Daly AK, Aithal GP. Daly AK, et al. Semin Vasc Med. 2003 Aug;3(3):231-8. doi: 10.1055/s-2003-44458. Semin Vasc Med. 2003. PMID: 15199455 Review.

10

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. Sconce EA, et al. Among authors: daly ak. Blood. 2005 Oct 1;106(7):2329-33. doi: 10.1182/blood-2005-03-1108. Epub 2005 Jun 9. Blood. 2005. PMID: 15947090 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

304 results

Search Page